Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

DiaMedica Therapeutics Inc. (the "Company") held its 2025 Annual General Meeting of Shareholders (the "2025 AGM") on May 15, 2025. As of the close of business on March 18, 2025, the record date for the 2025 AGM, there were 42,855,660 voting common shares, no par value, of the Company ("Common Shares") outstanding and entitled to vote at the 2025 AGM. Each Common Share was entitled to one vote. Shareholders holding an aggregate of 19,344,190 Common Shares entitled to vote at the 2025 AGM, representing 45.1% of the outstanding Common Shares as of the record date, and which constituted a quorum thereof, were present in person or represented by proxy at the 2025 AGM.

At the 2025 AGM, the Company's shareholders considered three voting proposals, each of which is described in detail in the Company's definitive proxy statement for the 2025 AGM filed with the United States Securities and Exchange Commission on March 28, 2025.

The final voting results of each voting proposal brought before a vote of the Company's shareholders at the 2025 AGM are set forth below:

Voting Proposal One - Election of Directors.

The seven director nominees proposed by the Board were elected to serve as members of the Board until the next annual general meeting of shareholders and until their respective successors are duly elected and qualified by the following final voting results:

Voting Proposal Two - Appointment of Independent Registered Public Accounting Firm and Authorization to Fix Remuneration.

The voting proposal to appoint Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 and authorize the Board to fix the Company's independent registered public accounting firm's remuneration was approved by the following final voting results:

Voting Proposal Three - Advisory Approval of Executive Compensation

The voting proposal to approve, on an advisory (non-binding) basis, the Company's executive compensation was approved by the following final voting results: